Şunu aradınız:: azacitidine (Maltaca - İngilizce)

kunjett 1 fih 100 mg azacitidine.
1 vial contains 100 mg azacitidine.

fih is- sustanza attiva azacitidine.
it contains the active substance azacitidine.

kunjett wieħed fih 100 mg azacitidine.
one vial contains 100 mg azacitidine.

kull kunjett fih 100 mg ta’ azacitidine.
each vial contains100 mg azacitidine.

vidaza fih is- sustanza attiva msejħa azacitidine.
vidaza contains the active substance azacitidine.

l-għeja ġiet irrappurtata bl-użu ta’ azacitidine.
fatigue has been reported with the use of azacitidine.

daqs tal- pakkett: kunjett 1 ta ’ 100 mg azacitidine.
1 vial of 100 mg azacitidine.

iċ-ċelluli li ma jipproliferawx huma relattivament insensittivi għal azacitidine.
non-proliferating cells are relatively insensitive to azacitidine.

vidaza 25 mg/ml trab għal suspensjoni għall-injezzjoni azacitidine
vidaza 25 mg/ml powder for suspension for injection azacitidine

wara r-rikostituzzjoni, kull ml ta' suspensjoni jkun fih 25 mg azacitidine.
after reconstitution, each ml suspension contains 25 mg azacitidine.

każ wieħed ta ’ doża eċċessiva b’ azacitidine kien rrappurtat matul provi kliniċi.
one case of overdose with azacitidine was reported during clinical trials.

azacitidine għandu effett żgħir jew effett moderat fuq il-ħila biex issuq u tħaddem magni.
azacitidine has minor or moderate influence on the ability to drive and use machines.

vidaza 25 mg/ ml trab għal suspensjoni għall- injezzjoni azacitidine użu għal taħt il- ġilda
vidaza 25 mg/ml powder for suspension for injection azacitidine subcutaneous use

il-karċinoġeneċità potenzjali ta’ azacitidine kienet evalwata fil- ġrieden u fil-firien.
the potential carcinogenicity of azacitidine was evaluated in mice and rats.

ma saru l- ebda studji kliniċi formali dwar l- interazzjoni tal- mediċina b’ azacitidine.
no formal clinical drug interaction studies with azacitidine have been conducted.

m’hemm l-ebda dejta umana fuq l-effett ta’ azacitidine fuq il-fertilità.
there are no human data on the effect of azacitidine on fertility.

azacitidine jinduċi kemm mutazzjonijiet tal-ġeni kif ukoll aberazzjonijiet kromosomali f’sistemi ta’ ċelluli batterjali u mammiferi in vitro.
azacitidine induces both gene mutations and chromosomal aberrations in bacterial and mammalian cell systems in vitro.

jekk azacitidine rikostitwit imiss mal-ġilda, aħsel immedjatament u bir-reqqa bis-sapun u bl-ilma.
if reconstituted azacitidine comes into contact with the skin, immediately and thoroughly wash with soap and water.

wara r-rikostituzzjoni kull millilitru ta’ suspensjoni ser ikun fih 25 mg ta’ azacitidine (100 mg/4 ml).
after reconstitution each ml of suspension will contain 25 mg of azacitidine (100 mg/4 ml).

mhux magħruf jekk azacitidine jew il-metaboliti tiegħu jiġux eliminat/i mill-ħalib tas-sider tal- bniedem.
it is not known whether azacitidine or its metabolites are excreted in human milk.